FNCH
Finch Therapeutics Group, Inc.Company Information
- Company Name
- Finch Therapeutics Group, Inc.
- CIK
- CIK0001733257
- Category
- <br>Emerging growth company
- Ticker: Exchange
- FNCH: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- FNCH
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-06-09
- Last sale
- 2024-03-28
- Shares purchased (TTM)
- 5,010
- Shares sold (TTM)
- 8,112
Institutional Sentiment
- As of
- 2024-06-30
- Institutional shares owned
- 21,206
- Shares outstanding
- 1,605,763
- Ownership
- 1.32%
Earnings Market Reaction
- Filing date
- 2024-08-13
- Price on filing date
- —
- 1-month reaction
- 24.28%
- 3-month reaction
- 20.42%
Balance Sheet
Values in millions ($)| Line item | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 16 | 21 | 25 | 29 | 34 | 42 | 71 | 85 | 105 | 107 | 133 | 149 | ||||||
| Accounts Receivable Net Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 17 | 21 | 26 | 30 | 36 | 43 | 75 | 91 | 111 | 123 | 143 | 156 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 0 | 1 | 1 | 2 | 2 | 3 | 5 | 6 | 16 | 9 | 5 | ||||||
| Due From Related Parties Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 16 | 17 | 18 | 19 | 20 | 20 | ||||||
| Operating Lease Right Of Use Asset | 25 | 26 | 27 | 27 | 27 | 32 | 33 | 40 | 41 | 5 | 5 | 5 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | - | - | 0 | 0 | 0 | 0 | 4 | 4 | 5 | 5 | 5 | 4 | ||||||
| Unamortized Debt Issuance Expense | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Assets | 46 | 50 | 55 | 59 | 67 | 79 | 163 | 188 | 228 | 205 | 225 | 233 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 5 | 4 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Goodwill | - | - | - | - | - | - | 0 | 0 | 18 | 18 | 18 | 18 | ||||||
| Liabilities Current | 4 | 3 | 4 | 5 | 10 | 13 | 15 | 14 | 15 | 17 | 15 | 9 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 5 | 1 | 1 | 1 | ||||||
| Deferred Income Tax Liabilities Net | - | - | 0 | 0 | 0 | 0 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Debt Noncurrent | - | - | 0 | 0 | 0 | 0 | 15 | 15 | 15 | - | 0 | 0 | ||||||
| Due To Related Parties Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 27 | 28 | 28 | 29 | 29 | 33 | 34 | 35 | 36 | 5 | 5 | 5 | ||||||
| Contract With Customer Liability Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 31 | 31 | 32 | 34 | 39 | 46 | 67 | 67 | 69 | 25 | 23 | 13 | ||||||
| Contract With Customer Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Deferred Rent Credit Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 1 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 14 | 19 | 23 | 26 | 28 | 35 | 96 | 121 | 159 | 180 | 202 | 220 | ||||||
| Additional Paid In Capital Common Stock | 373 | 373 | 373 | 373 | 373 | 372 | 371 | 369 | 367 | 365 | 363 | 362 | ||||||
| Retained Earnings Accumulated Deficit | -359 | -354 | -350 | -347 | -345 | -340 | -276 | -249 | -208 | -186 | -161 | -142 | ||||||
| Liabilities And Stockholders Equity | 46 | 50 | 55 | 59 | 67 | 79 | 163 | 188 | 228 | 205 | 225 | 233 | ||||||
| Temporary Equity Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | - | - | 10 | - | ||||||
| Temporary Equity Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Temporary Equity Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | 0 | ||||||
| Temporary Equity Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Series A Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Series B Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Series C Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Series D Redeemable Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialFinch Therapeutics Group, Inc. (FNCH) — SEC Financial Statements & Analysis
Finch Therapeutics Group, Inc. (FNCH) is a biological products, (no diagnostic substances) company, incorporated in DE. Finch Therapeutics Group, Inc. trades on OTC as: FNCH. Finch Therapeutics Group, Inc. (FNCH)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-13. Based on that filing, On profitability, Finch Therapeutics Group, Inc. posts an operating margin of -78374.77%, a net margin of -69863.55%, a Return on Equity (ROE) of -67.28%, a Return on Assets (ROA) of -25.20%, and a Return on Invested Capital (ROIC) of -213.16%. Per share, it reports EPS of $-8.82, diluted EPS of $-8.82, free cash flow per share of $-11.25, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -89.63% year-over-year, and EPS growth of -89.64% year-over-year. On the balance sheet, it maintains a current ratio of 3.87x, a quick ratio of 3.59x, working capital of $12.82M, a debt-to-equity ratio of 2.21x, a debt ratio of 0.69, free cash flow of $-18.07M (TTM), and net debt of $-16.04M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-8.82
- ROE TTM
- -67.28%
- ROA TTM
- -25.20%
- Debt To Equity
- 2.21x
- Free Cash Flow TTM
- $-18.07M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2024-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Finch Therapeutics Group, Inc. in?
Finch Therapeutics Group, Inc. (FNCH) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does FNCH trade on?
Finch Therapeutics Group, Inc. (FNCH) trades on the OTC.
Where is Finch Therapeutics Group, Inc. incorporated?
Finch Therapeutics Group, Inc. is incorporated in DE.
When was Finch Therapeutics Group, Inc. (FNCH)'s most recent SEC filing?
Finch Therapeutics Group, Inc. (FNCH)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-13.
What is FNCH's EPS (earnings per share)?
Finch Therapeutics Group, Inc. (FNCH)'s trailing twelve month EPS is $-8.82 as of 2024-06-30.
What is FNCH's ROE (return on equity)?
Finch Therapeutics Group, Inc. (FNCH)'s trailing twelve month Return on Equity (ROE) is -67.28% as of 2024-06-30.
What is FNCH's ROA (return on assets)?
Finch Therapeutics Group, Inc. (FNCH)'s trailing twelve month Return on Assets (ROA) is -25.20% as of 2024-06-30.
What is FNCH's ROIC (return on invested capital)?
Finch Therapeutics Group, Inc. (FNCH)'s trailing twelve month Return on Invested Capital (ROIC) is -213.16% as of 2022-12-31.